CD8A and neoplasm: Firstly, previous studies reported that the CD4/CD8 ratio was significantly lower in patients with higher tumor load and plasma concentration of Epstein-Barr virus DNA pre-treatment, indicating a higher risk of distant metastasis [12, 18].